Literature DB >> 30154637

Landmark Trials in Cardiology in 2017-Celebrating 40 Years of Angioplasty.

Akshyaya Pradhan1, Pravesh Vishwakarma1, Rishi Sethi1.   

Abstract

Cardiovascular (CV) diseases continue to be the leading cause of morbidity and mortality worldwide. Significant progress has been made in the management of coronary artery disease (CAD) and acute coronary syndrome (ACS) over the past 3 decades. The year 2017 marks 40th anniversary of the first coronary angioplasty performed by Andreas Gruentzig in the year 1977. Evidence-based medicine and research has been the key driving force of these positive outcomes. The year 2017 witnessed presentation of several landmark studies at major meetings and many of them getting published in literature simultaneously. These trials evaluated wide range of issues from novel percutaneous coronary intervention (PCI) strategies to newer drugs to innovative devices in management of CAD. We selectively discuss a few major landmark studies that have the potential to alter our daily practice in 2018.

Entities:  

Keywords:  STEMI; cardiogenic shock; dual antiplatelet; evolocumab; fractional flow reserve (FFR); multivessel disease; rivaroxaban

Year:  2018        PMID: 30154637      PMCID: PMC6103756          DOI: 10.1055/s-0038-1661376

Source DB:  PubMed          Journal:  Int J Angiol        ISSN: 1061-1711


  29 in total

1.  Rivaroxaban in patients with a recent acute coronary syndrome.

Authors:  Jessica L Mega; Eugene Braunwald; Stephen D Wiviott; Jean-Pierre Bassand; Deepak L Bhatt; Christoph Bode; Paul Burton; Marc Cohen; Nancy Cook-Bruns; Keith A A Fox; Shinya Goto; Sabina A Murphy; Alexei N Plotnikov; David Schneider; Xiang Sun; Freek W A Verheugt; C Michael Gibson
Journal:  N Engl J Med       Date:  2011-11-13       Impact factor: 91.245

2.  Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial.

Authors:  Friedrich W Mohr; Marie-Claude Morice; A Pieter Kappetein; Ted E Feldman; Elisabeth Ståhle; Antonio Colombo; Michael J Mack; David R Holmes; Marie-angèle Morel; Nic Van Dyck; Vicki M Houle; Keith D Dawkins; Patrick W Serruys
Journal:  Lancet       Date:  2013-02-23       Impact factor: 79.321

3.  Fractional Flow Reserve-Guided Multivessel Angioplasty in Myocardial Infarction.

Authors:  Pieter C Smits; Mohamed Abdel-Wahab; Franz-Josef Neumann; Bianca M Boxma-de Klerk; Ketil Lunde; Carl E Schotborgh; Zsolt Piroth; David Horak; Adrian Wlodarczak; Paul J Ong; Rainer Hambrecht; Oskar Angerås; Gert Richardt; Elmir Omerovic
Journal:  N Engl J Med       Date:  2017-03-18       Impact factor: 91.245

4.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Authors:  John W Eikelboom; Stuart J Connolly; Jackie Bosch; Gilles R Dagenais; Robert G Hart; Olga Shestakovska; Rafael Diaz; Marco Alings; Eva M Lonn; Sonia S Anand; Petr Widimsky; Masatsugu Hori; Alvaro Avezum; Leopoldo S Piegas; Kelley R H Branch; Jeffrey Probstfield; Deepak L Bhatt; Jun Zhu; Yan Liang; Aldo P Maggioni; Patricio Lopez-Jaramillo; Martin O'Donnell; Ajay K Kakkar; Keith A A Fox; Alexander N Parkhomenko; Georg Ertl; Stefan Störk; Matyas Keltai; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Peter B Verhamme; Dragos Vinereanu; Jae-Hyung Kim; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; P Gabriel Steg; Kaj P Metsarinne; Nancy Cook Bruns; Frank Misselwitz; Edmond Chen; Darryl Leong; Salim Yusuf
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

5.  Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.

Authors:  Dirk Sibbing; Dániel Aradi; Claudius Jacobshagen; Lisa Gross; Dietmar Trenk; Tobias Geisler; Martin Orban; Martin Hadamitzky; Béla Merkely; Róbert Gábor Kiss; András Komócsi; Csaba A Dézsi; Lesca Holdt; Stephan B Felix; Radoslaw Parma; Mariusz Klopotowski; Robert H G Schwinger; Johannes Rieber; Kurt Huber; Franz-Josef Neumann; Lukasz Koltowski; Julinda Mehilli; Zenon Huczek; Steffen Massberg
Journal:  Lancet       Date:  2017-08-28       Impact factor: 79.321

6.  2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).

Authors:  Marco Valgimigli; Héctor Bueno; Robert A Byrne; Jean-Philippe Collet; Francesco Costa; Anders Jeppsson; Peter Jüni; Adnan Kastrati; Philippe Kolh; Laura Mauri; Gilles Montalescot; Franz-Josef Neumann; Mate Petricevic; Marco Roffi; Philippe Gabriel Steg; Stephan Windecker; Jose Luis Zamorano; Glenn N Levine
Journal:  Eur Heart J       Date:  2018-01-14       Impact factor: 29.983

Review 7.  Coronary balloon angioplasty, stents, and scaffolds.

Authors:  Robert A Byrne; Gregg W Stone; John Ormiston; Adnan Kastrati
Journal:  Lancet       Date:  2017-08-19       Impact factor: 79.321

8.  Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial.

Authors:  E Magnus Ohman; Matthew T Roe; P Gabriel Steg; Stefan K James; Thomas J Povsic; Jennifer White; Frank Rockhold; Alexei Plotnikov; Hardi Mundl; John Strony; Xiang Sun; Steen Husted; Michal Tendera; Gilles Montalescot; M Cecilia Bahit; Diego Ardissino; Héctor Bueno; Marc J Claeys; Jose C Nicolau; Jan H Cornel; Shinya Goto; Róbert Gábor Kiss; Ümit Güray; Duk-Woo Park; Christoph Bode; Robert C Welsh; C Michael Gibson
Journal:  Lancet       Date:  2017-03-18       Impact factor: 79.321

9.  Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock.

Authors:  J S Hochman; L A Sleeper; J G Webb; T A Sanborn; H D White; J D Talley; C E Buller; A K Jacobs; J N Slater; J Col; S M McKinlay; T H LeJemtel
Journal:  N Engl J Med       Date:  1999-08-26       Impact factor: 91.245

10.  Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study.

Authors:  Javier Escaned; Carlos Collet; Nicola Ryan; Giovanni Luigi De Maria; Simon Walsh; Manel Sabate; Justin Davies; Maciej Lesiak; Raul Moreno; Ignacio Cruz-Gonzalez; Stephan P Hoole; Nick Ej West; J J Piek; Azfar Zaman; Farzin Fath-Ordoubadi; Rodney H Stables; Clare Appleby; Nicolas van Mieghem; Robert Jm van Geuns; Neal Uren; Javier Zueco; Pawel Buszman; Andres Iñiguez; Javier Goicolea; David Hildick-Smith; Andrzej Ochala; Dariusz Dudek; Colm Hanratty; Rafael Cavalcante; Arie Pieter Kappetein; David P Taggart; Gerrit-Anne van Es; Marie-Angèle Morel; Ton de Vries; Yoshinobu Onuma; Vasim Farooq; Patrick W Serruys; Adrian P Banning
Journal:  Eur Heart J       Date:  2017-11-07       Impact factor: 29.983

View more
  1 in total

Review 1.  Ideal P2Y12 Inhibitor in Acute Coronary Syndrome: A Review and Current Status.

Authors:  Akshyaya Pradhan; Aashish Tiwari; Giuseppe Caminiti; Chiara Salimei; Saverio Muscoli; Rishi Sethi; Marco Alfonso Perrone
Journal:  Int J Environ Res Public Health       Date:  2022-07-23       Impact factor: 4.614

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.